NMTC Valuation

NeuroOne Medical Technologies Corp

Add to Watchlist

Advanced Chart

0.887

-0.015(-1.664%)1D

Overview
Forecast
Valuation
Earnings

NMTC Relative Valuation

NMTC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NMTC is overvalued; if below, it's undervalued.

Historical Valuation

NeuroOne Medical Technologies Corp (NMTC) is now in the Overvalued zone, suggesting that its current forward PS ratio of 5.60 is considered Overvalued compared with the five-year average of -3.15. The fair price of NeuroOne Medical Technologies Corp (NMTC) is between 0.59 to 0.75 according to relative valuation methord. Compared to the current price of 0.81 USD , NeuroOne Medical Technologies Corp is Overvalued By 8.72%.

Relative Value

Fair Zone

0.59-0.75

Current Price：0.81

8.72%

Overvalued

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

25.13

P/B

Median3y

8.08

Median5y

8.39

-11.07

FCF Yield

Median3y

-37.99

Median5y

-32.31

Competitors Valuation Multiple

The average P/S ratio for NMTC's competitors is 7.95, providing a benchmark for relative valuation. NeuroOne Medical Technologies Corp Corp (NMTC) exhibits a P/S ratio of 4.89, which is -38.53% above the industry average. Given its robust revenue growth of 0.67%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

NMTC.O

NeuroOne Medical Technologies Corp

4.89

Average P/S: 7.95

0.67%